Cdk5 Is a Key Factor in Tau Aggregation and Tangle Formation In Vivo

Tau aggregation is a common feature of neurodegenerative diseases such as Alzheimer's disease, and hyperphosphorylation of tau has been implicated as a fundamental pathogenic mechanism in this process. To examine the impact of cdk5 in tau aggregation and tangle formation, we crossed transgenic mice overexpressing the cdk5 activator p25, with transgenic mice overexpressing mutant (P301L) human tau. Tau was hyperphosphorylated at several sites in the double transgenics, and there was a highly significant accumulation of aggregated tau in brainstem and cortex. This was accompanied by increased numbers of silver-stained neurofibrillary tangles (NFTs). Insoluble tau was also associated with active GSK. Thus, cdk5 can initiate a major impact on tau pathology progression that probably involves several kinases. Kinase inhibitors may thus be beneficial therapeutically.

[1]  I. Grundke‐Iqbal,et al.  Hyperphosphorylation induces self-assembly of τ into tangles of paired helical filaments/straight filaments , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[2]  I. Grundke‐Iqbal,et al.  Involvement of aberrant glycosylation in phosphorylation of tau by cdk5 and GSK‐3β , 2002, FEBS letters.

[3]  Khadija Iqbal,et al.  Phosphorylation of tau at both Thr 231 and Ser 262 is required for maximal inhibition of its binding to microtubules. , 1998, Archives of biochemistry and biophysics.

[4]  E. Mandelkow,et al.  Structure of tau protein and assembly into paired helical filaments. , 2000, Biochimica et biophysica acta.

[5]  R. Maccioni,et al.  A Cdk5-p35 stable complex is involved in the beta-amyloid-induced deregulation of Cdk5 activity in hippocampal neurons. , 2001, Experimental cell research.

[6]  A. Takashima,et al.  Role of GSK‐3β in Alzheimer's disease pathology , 2002 .

[7]  E. Matsubara,et al.  Aβ amyloidosis induces the initial stage of tau accumulation in APPSw mice , 2001, Neuroscience Letters.

[8]  R. Aebersold,et al.  A brain-specific activator of cyclin-dependent kinase 5 , 1994, Nature.

[9]  R. Nixon,et al.  Active site-directed antibodies identify calpain II as an early-appearing and pervasive component of neurofibrillary pathology in Alzheimer's disease , 1997, Brain Research.

[10]  P. Davies,et al.  A preparation of Alzheimer paired helical filaments that displays distinct tau proteins by polyacrylamide gel electrophoresis. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[11]  A. Takashima.  Tau protein I is essential for amyloid β-protein iduced neurotoxicity , 1993 .

[12]  A. Clark,et al.  Elevated neuronal Cdc2-like kinase activity in the Alzheimer disease brain , 1999, Neuroscience Research.

[13]  D. B. Evans,et al.  Characterization of the in vitro phosphorylation of human tau by tau protein kinase II (cdk5/p20) using mass spectrometry , 2001, Journal of neurochemistry.

[14]  M. Billingsley,et al.  Regulated phosphorylation and dephosphorylation of tau protein: effects on microtubule interaction, intracellular trafficking and neurodegeneration. , 1997, The Biochemical journal.

[15]  Veeranna,et al.  Mitogen-Activated Protein Kinases (Erk1,2) Phosphorylate Lys-Ser-Pro (KSP) Repeats in Neurofilament Proteins NF-H and NF-M , 1998, The Journal of Neuroscience.

[16]  I. Grundke‐Iqbal,et al.  Potentiation of GSK-3-catalyzed Alzheimer-like phosphorylation of human tau by cdk5 , 1997, Molecular and Cellular Biochemistry.

[17]  J. H. Wang,et al.  Brain proline-directed protein kinase phosphorylates tau on sites that are abnormally phosphorylated in tau associated with Alzheimer's paired helical filaments. , 1993, The Journal of biological chemistry.

[18]  E. Braak,et al.  Distribution, Levels, and Activity of Glycogen Synthase Kinase‐3 in the Alzheimer Disease Brain , 1997, Journal of neuropathology and experimental neurology.

[19]  E. Mandelkow,et al.  Phosphorylation of Ser262 strongly reduces binding of tau to microtubules: Distinction between PHF-like immunoreactivity and microtubule binding , 1993, Neuron.

[20]  P. Davies,et al.  Characterization of Pathology in Transgenic Mice Over-Expressing Human Genomic and cDNA Tau Transgenes , 2000, Neurobiology of Disease.

[21]  S. Shimohama,et al.  m-Calpain (calcium-activated neutral proteinase) in Alzheimer's disease brains , 1998, Neuroscience Letters.

[22]  R. Nitsch,et al.  Formation of Neurofibrillary Tangles in P301L Tau Transgenic Mice Induced by Aβ42 Fibrils , 2001, Science.

[23]  G. Bloom,et al.  A Role for Cyclin-Dependent Kinase(s) in the Modulation of Fast Anterograde Axonal Transport: Effects Defined by Olomoucine and the APC Tumor Suppressor Protein , 1998, The Journal of Neuroscience.

[24]  I. Everall,et al.  Rapid Tyrosine Phosphorylation of Neuronal Proteins Including Tau and Focal Adhesion Kinase in Response to Amyloid-β Peptide Exposure: Involvement of Src Family Protein Kinases , 2002, The Journal of Neuroscience.

[25]  R. Booher,et al.  Axonopathy, tau abnormalities, and dyskinesia, but no neurofibrillary tangles in p25‐transgenic mice , 2002, The Journal of comparative neurology.

[26]  L. Tsai,et al.  Neurotoxicity induces cleavage of p35 to p25 by calpain , 2000, Nature.

[27]  J. Hardy,et al.  Enhanced Neurofibrillary Degeneration in Transgenic Mice Expressing Mutant Tau and APP , 2001, Science.

[28]  Taro Saito,et al.  Truncation of CDK5 Activator p35 Induces Intensive Phosphorylation of Ser202/Thr205 of Human Tau* , 2002, The Journal of Biological Chemistry.

[29]  J. Bancroft,et al.  Theory and Practice of Histological Techniques , 1990 .

[30]  P. Davies,et al.  Deregulation of cdk5, Hyperphosphorylation, and Cytoskeletal Pathology in the Niemann–Pick Type C Murine Model , 2002, The Journal of Neuroscience.

[31]  K. Imahori,et al.  Characterization of tau phosphorylation in glycogen synthase kinase-3beta and cyclin dependent kinase-5 activator (p23) transfected cells. , 1998, Biochimica et biophysica acta.

[32]  L. Tsai,et al.  Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration , 1999, Nature.

[33]  K. Imahori,et al.  Analysis of phosphorylation of tau with antibodies specific for phosphorylation sites , 1995, Neuroscience Letters.

[34]  Georg G. Iggers,et al.  The Theory and Practice of History , 1983, History and Film.

[35]  L. Tsai,et al.  A survey of Cdk5 activator p35 and p25 levels in Alzheimer's disease brains , 2002, FEBS letters.

[36]  E. Matsubara,et al.  Abeta amyloidosis induces the initial stage of tau accumulation in APP(Sw) mice. , 2001, Neuroscience letters.

[37]  T. Downie,et al.  Theory and Practice of Histological Techniques Edited by J.D. Bancroft & A. Stevens, Churchill Livingstone, Edinburgh, 740 pages, £55.00 , 1990 .

[38]  D. Geschwind,et al.  Human Wild-Type Tau Interacts with wingless Pathway Components and Produces Neurofibrillary Pathology in Drosophila , 2002, Neuron.

[39]  D. Flaherty,et al.  Phosphorylation of human tau protein by microtubule‐associated kinases: GSK3β and cdk5 are key participants , 2000, Journal of neuroscience research.

[40]  René Hen,et al.  Decreased nuclear β‐catenin, tau hyperphosphorylation and neurodegeneration in GSK‐3β conditional transgenic mice , 2001 .

[41]  Satish K. Sharma,et al.  Direct interaction of soluble human recombinant tau protein with Aβ 1–42 results in tau aggregation and hyperphosphorylation by tau protein kinase II , 2002, FEBS letters.

[42]  M. Mercken,et al.  Glycogen Synthase Kinase-3β Phosphorylates Protein Tau and Rescues the Axonopathy in the Central Nervous System of Human Four-repeat Tau Transgenic Mice* , 2000, The Journal of Biological Chemistry.

[43]  R. D. Williams,et al.  Hyperphosphorylated tau and neurofilament and cytoskeletal disruptions in mice overexpressing human p25, an activator of cdk5. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[44]  M. Mullan,et al.  p35/Cdk5 pathway mediates soluble amyloid‐β peptide‐induced tau phosphorylation in vitro , 2002, Journal of neuroscience research.

[45]  K. Imahori,et al.  Tau protein kinase I is essential for amyloid beta-protein-induced neurotoxicity. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[46]  K. Imahori,et al.  Preferential labeling of Alzheimer neurofibrillary tangles with antisera for tau protein kinase (TPK) I/glycogen synthase kinase-3β and cyclin-dependent kinase 5, a component of TPK II , 1996, Acta Neuropathologica.

[47]  H. Braak,et al.  Silver impregnation of Alzheimer's neurofibrillary changes counterstained for basophilic material and lipofuscin pigment. , 1988, Stain technology.

[48]  Wen-Lang Lin,et al.  Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein , 2000, Nature Genetics.

[49]  H. Wiśniewski,et al.  Microtubule-associated protein tau. A component of Alzheimer paired helical filaments. , 1986, The Journal of biological chemistry.

[50]  E. Mandelkow,et al.  Abnormal Alzheimer‐like phosphorylation of tau‐protein by cyclin‐dependent kinases cdk2 and cdk5 , 1993, FEBS letters.

[51]  R. Nitsch,et al.  Compartmentalized tau hyperphosphorylation and increased levels of kinases in transgenic mice , 2001, Neuroreport.